Bharat Biotech gets nod for nasal Covid-19 vaccine's phase-3 clinical trials

"Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce/stop transmission," the company said in a statement. The company aims to conduct clinical trials on 5,000 healthy people at nine locations in the country. If approved as a booster dose, the intranasal vaccine will be given six months after the second dose," the company said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/32FE9s2
via IFTTT